Health Care/Hospital

Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade

SEONGNAM, South Korea and ATLANTA, March 28, 2024 /PRNewswire/ --  Bridge Biotherapeutics (KQ288330) , a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr.Jessica M...

2024-03-29 06:00 4110

Harbour BioMed Reports Full Year 2023 Financial Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncol...

2024-03-28 22:10 3657

Keosaa Launches Debut Electric Toothbrush on Amazon for Enhanced Oral Care

NEW YORK, March 28, 2024 /PRNewswire/ -- In an exciting announcement for dental hygiene enthusiasts and tech-savvy consumers alike, Keosaa has just launched its latest line of electric toothbrushes for a brighter, healthier smile. As we celebrate Oral Health Month, there is a better time to upgra...

2024-03-28 21:00 1655

Primech Holdings Limited Provides Financial Updates and Corporate Highlights For the Six Months Ended September 30, 2023

SINGAPORE, March 28, 2024 /PRNewswire/ -- Primech Holdings Limited (Nasdaq: PMEC) ("Primech" or the "Company"), an established technology-driven facilities services provider in the public and private sectors operating mainly inSingapore , provides a financial and corporate update coincident with t...

2024-03-28 20:30 3417

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

SHANGHAI, March 28, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced it has entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland GmbH to start a c...

2024-03-28 19:00 2244

Tigermed Reports Full Year 2023 Results

HANGZHOU, China, March 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annua...

2024-03-28 18:31 3340

Ascentage Pharma Announces 2023 Annual Results

SUZHOU, China and ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023. During...

2024-03-27 22:30 2448

CARsgen Announced 2023 Annual Results

SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Annual Results. Business Highlights * Z...

2024-03-27 20:50 2364

Sanyou Bio: Sanyou's Intelligence-Enabled Innovative Biologics R&D Platform Leads in the New Era of Biological Drug Development

SHANGHAI, March 27, 2024 /PRNewswire/ -- Dr. Guojun Lang, founder and CEO of Sanyou Biopharmaceuticals provides industry insights: The new era sees the transition towards digitalization and intelligence. Following this trend, we have been thinking and planning the transformative path of digitali...

2024-03-27 20:00 1714

YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean

SHANGHAI, March 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a trailblazing biopharmaceutical company specializing in gene editing, is delighted to announce its participation in 2024 Cell & Gene Meeting on the Mediterranean. The event will take place fromApril 9th to 11th, 2024, at the esteemed...

2024-03-27 20:00 1505

Waterdrop declared a special cash dividend, the aggregate payment of which amounted to approximately US$15 million

BEIJING, March 27, 2024 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three months and full year endedDecember 31, 2023 and a special ca...

2024-03-27 14:35 2039

Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology

SEONGNAM, South Korea and AURORA, Colo., March 26, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) , a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr.Raul...

2024-03-27 06:00 711

Keymed Biosciences Announces 2023 Annual Results and Business Updates

* Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by theChina's NMPA and granted priority review. * Advanced a Phase III clinical study of Stapokibart for the treatment of CRSwNP in 2023. The results of t...

2024-03-27 01:16 1123

Datasea Enters into 5G AI Multimodal Communication Cooperation Agreement Expected to Expand its China 5G Services Revenue

The Agreement with an Estimated Value of $30 Million Supports its Revenue Guidance of$86 Million, a 1,128% Year-Over-Year Increase for its Full Fiscal Year BEIJING, March 26, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative ...

2024-03-26 22:00 1375

WuXi Biologics Reports Solid 2023 Annual Results

Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Million Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong Momentum Sustained Non-COVID Late-Phase and Commercial Manufacturing Revenue Grew by 101.7% Y-o-Y "R" in CRDMO Thrived with Extended Part...

2024-03-26 21:53 1890

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients

- New research published in Clinical Cancer Research shows significant improvement in distant recurrence-free survival with combined durvalumab and tremelimumab treatment, supported by Lunit SCOPE IO's analysis of tumor microenvironment SEOUL, South Korea, March 26, 2024 /PRNewswire/ -- Lunit (K...

2024-03-26 21:00 1230

PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition

NANJING, China, March 26, 2024 /PRNewswire/ -- PharmaBlock (Stock code: 300725.SZSE), a global, fully integrated CRDMOwith a focus on innovative chemistry and low-carbon manufacturing, is proud to announce that it has been awarded the 2024 CMO Excellence in Green Chemistry Award by the American ...

2024-03-26 20:00 1082

TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

* TU7710 has the potential to be a highly effective and long-acting treatment for bleeding episodes as well as for preventing bleeding during surgery or invasive procedures in hemophilia patients with inhibitors * Interim results from an ongoing Phase 1a study in healthy male volunteers will ...

2024-03-26 20:00 1058

Waterdrop Inc. Announces Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results and a Special Cash Dividend

BEIJING, March 26, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three months and full year en...

2024-03-26 18:00 1560

Full-Life Technologies Achieves Regulatory Milestone with Nuclear Permit, Advancing Radioisotope Facility Construction

GEMBLOUX, Belgium, March 25, 2024 /PRNewswire/ -- Full-Life Technologies ("Full-Life"), today announced the recent achievement of its subsidiary "Full-Life Technology Europe" has obtained a Nuclear Permit for a class IIA facility from the Belgium Federal Agency for Nuclear Control ("FANC"), auth...

2024-03-26 08:00 1047
1 ... 41424344454647 ... 277

Week's Top Stories